Trial Profile
A retrospective study to investigate that neutrophil to lymphocyte ratio is useful to predict the prognosis of advanced gastric cancer patients treated with Paclitaxel and Ramucirumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 25 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017